Company
Headquarters: Toronto, ON, Canada
Employees: 31
CEO: Mr. Christopher Seto
C$138.3 Million
CAD as of July 1, 2024
US$100.7 Million
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $204.45 B |
Danaher | $177.21 B |
Siemens Healthineers AG | $63.84 B |
DexCom, Inc. | $45.21 B |
Lonza Group Ltd | $39.85 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Spectral Medical Inc. has the following listings and related stock indices.
Stock: TSX: EDT wb_incandescent
Stock: FSX: SD4 wb_incandescent
Stock: OTC: EDTXF wb_incandescent